
    
      The decision to discontinue the development of AERxÂ® is not due to any safety concerns. An
      analysis concluded that fast-acting inhaled insulin in the form it is known today, is
      unlikely to offer significant clinical or convenience benefits over injections of modern
      insulin with pen devices.
    
  